Drug Trial Radar · NCT06664853
Open-Label Extension of EryDex Study IEDAT-04-2022
Last checked: Nov 19, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
101
Actual
Start
Dec 11, 2024
Primary completion
Jan 30, 2026
Study completion Jan 30, 2026
Sponsor
- Lead sponsor
- Quince Therapeutics S.p.A.Industry
- Sponsor type
- Industry
- Collaborators
- Biotrial
- First posted
- Oct 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an international, multi-center, prospective, open-label, non-comparative study aiming to provide access to treatment with EryDex to ataxia telangiectasia (A-T) patients who completed the IEDAT-04-2022 trial which studied the neurological effects of EryDex on subjects with ataxia telangiectasia (NEAT trial).
Conditions
- Ataxia Telangiectasia
Interventions
Dexamethasone sodium phosphateDrug
Dexamethasone Sodium Phosphate encapsulated in autologous erythrocytes and administered via intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse EventsTime frame: through study completion, up to approximately 13 months
- Number of Participants With Treatment Emergent Adverse Events Leading to Intervention DiscontinuationTime frame: through study completion, up to approximately 13 months
- Number of Participants With Serious Adverse EventsTime frame: through study completion, up to approximately 13 months
Locations
21 sites in 9 countries. Site status is shown where the registry gives one.
University of California Los Angeles (UCLA), Ataxia Center and HD Center of excellence
Los Angeles, California
The Johns Hopkins Hospital, Division of pediatric allergy and immunology
Baltimore, Maryland
Saint Peter's University Hospital, Inc.
New Brunswick, New Jersey
Cincinnati Children's Hospital, Division of neurology
Cincinnati, Ohio
UT Health Houston, Department of pediatrics, division of child & adolescent neurology
Houston, Texas
Copenhagen University Hospital, Rigshospitalet, Department of Pediatric Neurology
Copenhagen, Denmark, Denmark
University Hospital Frankfurt, Pediatric and Adolescent Clinic
Frankfurt, Germany, Germany
IKF Pneumologie GmbH & Co. KG; Institut für klinische Forschung Pneumologie Clinical Research Center Respiratory Diseases
Frankfurt am Main, Hesse, Germany
Spedali Civili di Brescia, Pediatric immunology department
Brescia, Italy, Italy
Policlinico Umberto I, La sapienza University, Department of neurosciences and menthal health
Roma, Italy, Italy
Oslo University Hospital, Rikshospitalet, Division of Pediatric and Adolescent Medicine, Norwegian National Unit for Newborn Screening
Oslo, Norway, Norway
MedPolonia sp zoo
Poznan, Poland
Instytut "Pomnik-Centrum Zdrowia Dziecka", Immunology clinic
Warsaw, Poland
Universitary Hospital Virgen del Rocío
Seville, Spain
Hospital Universitari Vall d'Hebron, Department of pediatric neurology
Barcelona, Spain, Spain
Hospital Universitario La Paz, Department of pediatric neurology
Madrid, Spain, Spain
University Children's Hospital Zürich - Eleonore Foundation
Zurich, Switzerland
University Hospitals Birmingham NHS Foundation Trust
Birmingham, United Kingdom
St George's University Hospitals NHS Foundation Trust, Centre for Neonatal and Paediatric Infection
London, United Kingdom
Great Ormond Street Hospital for Children, Zayed Centre for Research
London, United Kingdom, United Kingdom
Nottingham Children's Hospital, Queen's Medical Center, Children's neurology
Nottingham, United Kingdom, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.